Financial Perspectives Inc Boosts Holdings in argenx SE (NASDAQ:ARGX)

Financial Perspectives Inc increased its stake in shares of argenx SE (NASDAQ:ARGX) by 39.4% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 145 shares of the company’s stock after purchasing an additional 41 shares during the period. Financial Perspectives Inc’s holdings in argenx were worth $89,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the company. FMR LLC increased its position in shares of argenx by 35.9% in the third quarter. FMR LLC now owns 4,793,472 shares of the company’s stock valued at $2,598,445,000 after buying an additional 1,265,486 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of argenx by 0.4% during the 3rd quarter. Janus Henderson Group PLC now owns 2,479,207 shares of the company’s stock worth $1,343,797,000 after buying an additional 10,975 shares in the last quarter. Wellington Management Group LLP grew its holdings in argenx by 13.0% during the 3rd quarter. Wellington Management Group LLP now owns 482,346 shares of the company’s stock valued at $261,470,000 after buying an additional 55,617 shares during the last quarter. Alkeon Capital Management LLC boosted its holdings in argenx by 15.0% in the third quarter. Alkeon Capital Management LLC now owns 345,000 shares of the company’s stock valued at $187,018,000 after acquiring an additional 45,000 shares during the last quarter. Finally, Jennison Associates LLC raised its position in argenx by 27.0% in the fourth quarter. Jennison Associates LLC now owns 302,149 shares of the company’s stock valued at $185,821,000 after purchasing an additional 64,183 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Stock Performance

Shares of ARGX stock opened at $639.00 on Wednesday. The company has a market capitalization of $38.83 billion, a price-to-earnings ratio of -726.14 and a beta of 0.58. The company’s 50-day moving average is $640.74 and its 200 day moving average is $584.63. argenx SE has a one year low of $349.86 and a one year high of $678.21.

Wall Street Analysts Forecast Growth

ARGX has been the subject of a number of research reports. Baird R W downgraded argenx from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 1st. Oppenheimer reiterated an “outperform” rating and issued a $675.00 price objective (up from $646.00) on shares of argenx in a report on Thursday, November 21st. Robert W. Baird cut shares of argenx from an “outperform” rating to a “neutral” rating and upped their price target for the company from $515.00 to $650.00 in a report on Friday, November 1st. Guggenheim increased their price target on shares of argenx from $585.00 to $665.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Finally, JMP Securities increased their price target on shares of argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $658.39.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.